Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vapreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 known ✓ | P30874 | 16/20 | 0.81 |
| ▸ | SSTR5 known ✓ | P35346 | 15/20 | 0.81 |
| ▸ | SSTR3 known ✓ | P32745 | 8/20 | 0.78 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.78 |
| ▸ | SSTR4 | P31391 | 7/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vapreotide SCHEMBL4827 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL6369050 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL4826 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL31632623 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL30163296 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29580907 | 0.99 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL294911 | 0.99 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29384009 | 0.99 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL5200070 | 0.97 | SSTR2 (0.78) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| SCHEMBL23482743 | 0.97 | SSTR5 (0.78) | SSTR2SSTR5SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827651-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-28 | — | — | US | claimed |
| US-20220270454-A1 | TREATMENT OF KIDNEY DISEASES ASSOCIATED WITH ELEVATED AVP | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-08-25 | — | — | US | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4095608-B1 | ELECTROSTATIC IMAGE DEVELOPING TONER | FUJIFILM BUSINESS INNOVATION CORP (JP) | 2026-04-29 | — | — | EP | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-12486294-B2 | Radioisotope labeled compound for imaging or treatment of prostate cancer | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-12-02 | — | — | US | disclosed |
| WO-2025233437-A1 | POLYPEPTIDE COMPRISING A CAPSID PROTEIN SEQUENCE | A-SPECTAR GMBH (AT) | 2025-11-13 | — | — | WO | disclosed |
| EP-4647438-A1 | POLYPEPTIDE COMPRISING A CAPSID PROTEIN SEQUENCE | A-Spectar GmbH (AT) | 2025-11-12 | — | — | EP | disclosed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | disclosed |
| US-11392052-B2 | Electrostatic image developing toner, electrostatic image developer, toner cartridge, process cartridge, image forming apparatus, and image forming method | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2022-07-19 | — | — | US | disclosed |
| US-11354990-B2 | Treatment of kidney diseases associated with elevated AVP | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-06-07 | — | — | US | disclosed |
| CN-107203103-B | Image forming method and image forming apparatus | 富士胶片商业创新有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-20220088150-A1 | Octreotide Microsphere-Based Arterial Embolization for Treating Obesity | BIOVENA SCIENCE LLC (US) | 2022-03-24 | — | — | US | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | SSTR2 62/4885SSTR5 126/4885SSTR3 79/4885 |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | SSTR2 2069/4885SSTR5 3066/4885SSTR3 2297/4885 |
| US-12486294-B2 | Radioisotope labeled compound for imaging or treatment of prostate cancer | ARGLU1, KLK3, GLUL | SSTR2 1231/4885SSTR5 517/4885SSTR3 872/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | SSTR2 299/4885SSTR5 630/4885SSTR3 228/4885 |
| US-11354990-B2 | Treatment of kidney diseases associated with elevated AVP | AVPR2, PKD1, AVPR1A | SSTR2 1518/4885SSTR5 1178/4885SSTR3 1039/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | SSTR2 119/4885SSTR5 68/4885SSTR3 55/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | SSTR2 501/4885SSTR5 106/4885SSTR3 217/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | SSTR2 2189/4885SSTR5 2683/4885SSTR3 2107/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | SSTR2 988/4885SSTR5 503/4885SSTR3 479/4885 |
| US-11827651-B2 | Organic electroluminescent materials and devices | SSB, L1CAM, LEF1 | SSTR2 2395/4885SSTR5 4107/4885SSTR3 3010/4885 |
| US-20220270454-A1 | TREATMENT OF KIDNEY DISEASES ASSOCIATED WITH ELEVATED AVP | AVPR2, PKD1, AVPR1A | SSTR2 1501/4885SSTR5 1145/4885SSTR3 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.